Regeneron’s Single Dose Monoclonal Antibodies Drug REDUCES Risk Of Contracting Covid

Regeneron Pharmaceuticals announced today that the results of a double-blind, placebo-controlled Phase 3 trial conducted alongside the National Institute of Allergy and Infectious Diseases (NIAID) showed the company’s single-dose REGEN-COV had positive effects at reducing the risk of contracting Covid in uninfected participants.

According to the company’s release, a single dose of REGEN-COV shows 81.6% effectiveness at preventing Covid infection. The antibody cocktail was designed to “block infectivity” of Covid, according to the release.

“The two potent, virus-neutralizing antibodies that form the cocktail bind non-competitively to the critical receptor binding domain of the virus’s spike protein, which diminishes the ability of mutant viruses to escape treatment and protects against spike variants that have arisen in the human population,” Regeneron Pharmaceuticals stated.

Dr. Myron Cohen, who leads the monoclonal antibody research, is the Director of the Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill.

Dr. Cohen praised the results for the Covid prevention, saying that the “new data demonstrate(s) how a single dose of REGEN-COV can help protect people from COVID-19 for many months after administration.” He continued his admiration for the drug saying, “these results demonstrate that REGEN-COV has the potential to provide long-lasting immunity from SARS-CoV-2 infection, a result particularly important to those who do not respond to COVID-19 vaccines, including people who are immunocompromised.”

According to Regeneron’s release, the results for a single dose of REGEN-COV versus the placebo showed participants experienced:

  • “81.6% reduced risk of developing Covid-19 during the pre-specified follow-up period, between months 2-8.”
  • “81.5% reduced risk of developing Covid-19 at any time during the eight months after receiving REGEN-COV.”
  • “During the 8-month assessment period, zero individuals in the REGEN-COV group were hospitalized due to Covid-19, compared to six individuals in the placebo group (1 person in the first month; 5 people during months 2-8). There were no deaths due to Covid-19 in any treatment group during the 8-month assessment period, and there were no new safety signals identified for REGEN-COV.”

President and Chief Scientific Officer at Regeneron, Dr. George Yancopoulos, said the data means relief the immunocompromised who can’t get vaccinated and “remain prisoners of the pandemic.” Dr. Yancopoulos said, “With infections still occurring despite widespread vaccination, the immunocompromised face an ongoing risk of encountering the virus during their daily lives.”

He said Regeneron Pharmaceuticals will be sharing their data with the approval boards “rapidly” to start getting REGEN-COV in the hands of “those in most need of protection.”

Join The Discussion

Related Posts